BDBM439347 US10633345, Compound 41e::US10689346, Compound 41e::US11203574, Compound 41e::US11230530, Compound 41e

SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1)C(F)(F)F

InChI Key InChIKey=QZQLNMURVWFZTC-UHFFFAOYSA-N

Data  5 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 439347   

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataIC50: 5.40nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataIC50: 19nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM439347(US10689346, Compound 41e | US10633345, Compound 41...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/17/2022
Entry Details
Go to US Patent